1. Home
  2. IMTE vs PCSA Comparison

IMTE vs PCSA Comparison

Compare IMTE & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMTE
  • PCSA
  • Stock Information
  • Founded
  • IMTE 2008
  • PCSA 2011
  • Country
  • IMTE Malaysia
  • PCSA United States
  • Employees
  • IMTE N/A
  • PCSA N/A
  • Industry
  • IMTE Consumer Electronics/Appliances
  • PCSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMTE Consumer Staples
  • PCSA Health Care
  • Exchange
  • IMTE Nasdaq
  • PCSA Nasdaq
  • Market Cap
  • IMTE 4.5M
  • PCSA 4.3M
  • IPO Year
  • IMTE N/A
  • PCSA N/A
  • Fundamental
  • Price
  • IMTE $1.21
  • PCSA $1.01
  • Analyst Decision
  • IMTE
  • PCSA Buy
  • Analyst Count
  • IMTE 0
  • PCSA 3
  • Target Price
  • IMTE N/A
  • PCSA $5.00
  • AVG Volume (30 Days)
  • IMTE 93.5K
  • PCSA 27.8K
  • Earning Date
  • IMTE 12-27-2024
  • PCSA 10-30-2024
  • Dividend Yield
  • IMTE N/A
  • PCSA N/A
  • EPS Growth
  • IMTE N/A
  • PCSA N/A
  • EPS
  • IMTE N/A
  • PCSA N/A
  • Revenue
  • IMTE $383,813.00
  • PCSA N/A
  • Revenue This Year
  • IMTE N/A
  • PCSA N/A
  • Revenue Next Year
  • IMTE N/A
  • PCSA N/A
  • P/E Ratio
  • IMTE N/A
  • PCSA N/A
  • Revenue Growth
  • IMTE 4.75
  • PCSA N/A
  • 52 Week Low
  • IMTE $1.06
  • PCSA $1.00
  • 52 Week High
  • IMTE $3.84
  • PCSA $17.40
  • Technical
  • Relative Strength Index (RSI)
  • IMTE 41.65
  • PCSA 28.20
  • Support Level
  • IMTE $1.15
  • PCSA $1.07
  • Resistance Level
  • IMTE $1.28
  • PCSA $1.15
  • Average True Range (ATR)
  • IMTE 0.25
  • PCSA 0.09
  • MACD
  • IMTE -0.05
  • PCSA -0.01
  • Stochastic Oscillator
  • IMTE 4.42
  • PCSA 2.54

About IMTE Integrated Media Technology Limited

Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: